1. P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?. (5th April 2022) Authors: Popat, R; Badros, A; Kumar, S; Rodriguez-Otero, P; Cohen, A; Manier, S; Voorhees, P; Gay, F; Rifkin, R; Martin, T; Chari, A; Weisel, K; Farooq, A; Jeng, B; Chng, W; Lee, H; Berdeja, J; Jadhav, V; Tosolini, A; Eliason, L Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL. (5th April 2022) Authors: Rodríguez-Otero, P; Shah, N; Munshi, N; Berdeja, J; Jagannath, S; Finney, O; Martin, N; Agarwal, A; Rowe, E; Campbell, T; San-Miguel, J Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗